行情

IMMP

IMMP

Immutep
NASDAQ

实时行情|Nasdaq Last Sale

3.700
+0.060
+1.65%
交易中 14:19 09/21 EDT
开盘
3.690
昨收
3.640
最高
3.719
最低
3.640
成交量
15.99万
成交额
--
52周最高
7.95
52周最低
1.530
市值
2.77亿
市盈率(TTM)
-0.9290
分时
5日
1月
3月
1年
5年
Immutep 将在 SITC 2021 上展示 IIb AIPAC 的最终总体生存数据作为最新海报展示
Immutep Limited (NASDAQ: IMMP) is pleased to announce it will report final Overall Survival (OS) data from its Phase IIb AIPAC clinical trial evaluating lead product candidate eftilagimod alpha ("efti" or "IMP321") in metastatic breast cancer at the Socie...
Benzinga · 9小时前
Brief-Immutep 在 Tacti-002 中完成了二线 PD-1/PD-L1 难治性 NSCLC 患者的招募
reuters.com · 09/01 12:36
Immutep 完成 TACTI-002二线 PD-1/PD-L1 难治性 NSCLC 患者的招募
Immutep Limited (NASDAQ: IMMP) announces that the last patient has been enrolled and safely dosed in Stage 2 of Part B of its Phase II TACTI-002 study (also designated KEYNOTE-798). This completes the recruitment of 2nd line PD-1/PD-L1 refractory non-small...
Benzinga · 09/01 09:27
Immutep 的中国合作伙伴 Eoc Pharma 扩大 Efti 试验管道;未披露条款
Immutep's Chinese Partner, Eoc Pharma, Expands Efti Trial Pipeline Sydney, Aug. 31, 2021 (GLOBE NEWSWIRE) -- SYDNEY, AUSTRALIA – 31 August 2021 – Immutep Limited ((ASX: IMM, NASDAQ:IMMP)
Benzinga · 08/31 12:08
Immutep 宣布获得 LAG-3 拮抗剂抗体 LAG525 的中国专利授权
SYDNEY, AUSTRALIA – 27 August 2021 – Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), is pleased to announce the grant of patent no. ZL201580013695.X
Benzinga · 08/27 12:02
The Daily Biotech Pulse: MorphoSys-Incyte Snag Europe Nod, Immutep 获得中国专利,Bolt Biotherapeutics Strike Oncology Collaboration
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26)
Benzinga · 08/27 11:35
甲骨文投资管理公司收购 Vir Biotechnology Inc、Forian Inc、SPDR Biotech ETF,...
GuruFocus News · 08/24 19:38
Boxer Capital, Llc 收购 ITeos Therapeutics Inc、Connect Biopharma Holdings、Nurix Therapeutics ...
GuruFocus News · 08/24 15:38
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解IMMP最新的财务预测,通过IMMP每股收益,每股净资产,每股现金流等数据分析Immutep近期的经营情况,然后做出明智的投资选择。
分析师评级

3位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测
分析师预测IMMP价格均价为8.34,最高价位8.90,最低价为7.91。
EPS
机构持股
总机构数: 34
机构持股: 897.27万
持股比例: 11.99%
总股本: 7,481.53万
类型机构数股数
增持
4
203.57万
建仓
17
249.73万
减持
4
21.77万
平仓
2
36.49万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
+1.55%
制药与医学研究
+0.77%
高管信息
Non-Executive Chairman
Russell Howard
Chief Executive Officer/Executive Director
Marc Voigt
Non-Executive Vice Chairman
Pete Meyers
Chief Operating Officer/General Counsel/Secretary
Deanne Miller
Chief Scientific Officer
Frederic Triebel
Non-Executive Director
Grant Chamberlain
暂无数据
IMMP 简况
Immutep Limited is an Australia-based biotechnology company. The Company is engaged in the development of LAG-3 immunotherapeutic products for cancer and autoimmune disease. The Company has four product candidates based on the LAG-3 immune control mechanism. Its lead product candidate, eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein, which is in later-stage clinical development for the treatment of cancer. Its second product candidate (IMP761) is in pre-clinical development for the treatment of autoimmune disease. The Company’s two licensed product candidates include Antagonist AB (LAG525) and Depleting AB (GSK‘781). The Company’s operates through its subsidiaries, which includes Immutep USA Inc, PRR Middle East FZ LLC, Immutep GmbH, Immutep Australia Pty Ltd, Immutep IP Pty Ltd and Immutep S.A.S.

微牛提供Immutep Ltd(NASDAQ-IMMP)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的IMMP股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易IMMP股票基本功能。